26.01 0.00 (0.00%)
After hours: 5:12PM EST
|Bid||24.80 x 3200|
|Ask||26.49 x 800|
|Day's Range||24.82 - 27.80|
|52 Week Range||15.73 - 40.75|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 26, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||41.25|
NEW YORK, Feb. 15, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Tuesday, February 26th at 4:30 p.m. Eastern Time to discuss its fourth quarter and full year 2018 financial results and report on pipeline and business progress. Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc., is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious and rare diseases. All six drugs were discovered by and are being co-developed with Ionis, a leader in antisense therapeutics, and are based on Ionis’ proprietary antisense technology.
FDA grants priority review to Pfizer's (PFE) regulatory filing looking for approval of pipeline candidate, tafamidis to treat transthyretin amyloid cardiomyopathy.
Alnylam dipped Monday after the FDA agreed to review an amyloidosis treatment from Pfizer in just six months. Pfizer's drug would treat patients with abnormal protein building in the heart.
Dow Jones' component Pfizer will take the lion's share of the amyloidosis treatment market — leaving Alnylam and Ionis to duke it out for the remainder, an analyst says.
On Monday, Nov. 5, Akcea Therapeutics (NASDAQ: AKCA ) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release. Earnings and Revenue Analysts ...
NEW YORK, NY / ACCESSWIRE / October 30, 2018 / U.S. equities continued to drop on Monday as losses in the energy and tech sectors added to the ongoing trade concerns between the U.S. and China. The Dow ...
The stock recovered from a surprising rejection at the end of August, but has tumbled once again in the first half of October.
NEW YORK, NY / ACCESSWIRE / October 10, 2018 / U.S. equities finished mostly lower on Tuesday as interest rate increases and rising bond yields continued to put pressure on stocks. The Dow Jones Industrial ...
NEW YORK, NY / ACCESSWIRE / October 8, 2018 / U.S. equities plunged on Friday as concerns over rising interest rates countered upbeat economic data. U.S. unemployment rate dropped to 3.7 percent, its lowest ...
After having one of its drugs rejected by the FDA in August, Cambridge biotech Akcea Therapeutics Inc. turned the tide on Friday, receiving approval for another treatment for a rare genetic disease. The FDA approved Tegsedi, known generically as inotersen, an RNA-based drug that is designed to treat a rare and often fatal genetic disease called hereditary ATTR amyloidosis, or hATTR amyloidosis. According to Akcea (Nasdaq: AKCA), the drug works by slowing down production of a protein that can build up and impede nervous system and organ functions.
Akcea Therapeutics Inc said on Friday its treatment, developed along with Ionis Pharmaceuticals , which targets a rare genetic disease was approved by the U.S. Food and Drug Administration. Akcea's once-weekly injection, Tegsedi, treats hereditary ATTR amyloidosis patients with polyneuropathy. Polyneuropathy, a symptom of the disease, is the simultaneous malfunction of peripheral nerves in the body resulting in tingling, numbness and kidney dysfunction.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 3) Amarin Corporation plc (NASDAQ: AMRN ) BIOLINERX Ltd/S ...